Paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
combined	combined	O	O	O	O
with	with	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
first-line	first-line	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
advanced	advanced	O	O	O	O
ovarian	ovarian	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
a	a	O	O	O	O
phase	phase	O	O	O	O
I	i	O	O	O	O
study	study	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
maximum	maximum	O	O	O	O
tolerated	tolerated	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
Taxol	taxol	CHEMICALS	O	OTHERS	I
;	;	O	O	O	O
Bristol-Myers	bristol-myers	O	O	O	O
Squibb	squibb	O	O	O	O
Company	company	O	O	O	O
,	,	O	O	O	O
Princeton	princeton	O	O	O	O
,	,	O	O	O	O
NJ	nj	O	O	O	O
)	)	O	O	O	O
given	given	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
3-hour	3-hour	O	O	O	O
infusion	infusion	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
administered	administered	O	O	O	O
every	every	O	O	O	O
21	21	O	O	O	O
days	days	O	O	O	O
to	to	O	O	O	O
women	women	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
ovarian	ovarian	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
doses	doses	O	O	O	O
were	were	O	O	O	O
escalated	escalated	O	O	O	O
as	as	O	O	O	O
follows	follows	O	O	O	O
:	:	O	O	O	O
level	level	O	O	O	O
1	1	O	O	O	O
,	,	O	O	O	O
135	135	O	O	O	O
mg/m2	mg/m2	O	O	O	O
;	;	O	O	O	O
level	level	O	O	O	O
2	2	O	O	O	O
,	,	O	O	O	O
160	160	O	O	O	O
mg/m2	mg/m2	O	O	O	O
;	;	O	O	O	O
level	level	O	O	O	O
3	3	O	O	O	O
,	,	O	O	O	O
185	185	O	O	O	O
mg/m2	mg/m2	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
level	level	O	O	O	O
4,210	4,210	O	O	O	O
mg/m2	mg/m2	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
fixed	fixed	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
levels	levels	O	O	O	O
1	1	O	O	O	O
through	through	O	O	O	O
4	4	O	O	O	O
was	was	O	O	O	O
given	given	O	O	O	O
to	to	O	O	O	O
achieve	achieve	O	O	O	O
an	an	O	O	O	O
area	area	O	O	O	O
under	under	O	O	O	O
the	the	O	O	O	O
concentration-time	concentration-time	O	O	O	O
curve	curve	O	O	O	O
(	(	O	O	O	O
AUC	auc	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
5	5	O	O	O	O
using	using	O	O	O	O
the	the	O	O	O	O
Calvert	calvert	O	O	O	O
formula	formula	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
levels	levels	O	O	O	O
5	5	O	O	O	O
and	and	O	O	O	O
6	6	O	O	O	O
the	the	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
was	was	O	O	O	O
targeted	targeted	O	O	O	O
at	at	O	O	O	O
AUCs	aucs	O	O	O	O
of	of	O	O	O	O
6	6	O	O	O	O
and	and	O	O	O	O
7.5	7.5	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
combined	combined	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
fixed	fixed	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
of	of	O	O	O	O
185	185	O	O	O	O
mg/m2	mg/m2	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
date	date	O	O	O	O
,	,	O	O	O	O
30	30	O	O	O	O
previously	previously	O	O	O	O
untreated	untreated	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
all	all	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
good	good	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
(	(	O	O	O	O
Eastern	eastern	O	O	O	O
Cooperative	cooperative	O	O	O	O
Oncology	oncology	O	O	O	O
Group	group	O	O	O	O
0	0	O	O	O	O
to	to	O	O	O	O
2	2	O	O	O	O
)	)	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
entered	entered	O	O	O	O
into	into	O	O	O	O
this	this	O	O	O	O
ongoing	ongoing	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
dose-limiting	dose-limiting	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
was	was	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
(	(	O	O	O	O
leukopenia	leukopenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
granulocytopenia	granulocytopenia	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
largely	largely	O	O	O	O
moderate	moderate	O	O	O	O
.	.	O	O	O	O

So	so	O	O	O	O
far	far	O	O	O	O
,	,	O	O	O	O
14	14	O	O	O	O
patients	patients	O	O	O	O
are	are	O	O	O	O
evaluable	evaluable	O	O	O	O
for	for	O	O	O	O
response	response	O	O	O	O
;	;	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
,	,	O	O	O	O
eight	eight	O	O	O	O
(	(	O	O	O	O
57	57	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
showed	showed	O	O	O	O
objective	objective	O	O	O	O
(	(	O	O	O	O
complete	complete	O	O	O	O
or	or	O	O	O	O
partial	partial	O	O	O	O
)	)	O	O	O	O
response	response	O	O	O	O
and	and	O	O	O	O
disease	disease	O	O	O	O
stabilized	stabilized	O	O	O	O
in	in	O	O	O	O
six	six	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
patient	patient	O	O	O	O
had	had	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
conclude	conclude	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
185	185	O	O	O	O
mg/m2	mg/m2	O	O	O	O
administered	administered	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
3-hour	3-hour	O	O	O	O
infusion	infusion	O	O	O	O
followed	followed	O	O	O	O
immediately	immediately	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
1-hour	1-hour	O	O	O	O
infusion	infusion	O	O	O	O
of	of	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
an	an	O	O	O	O
AUC	auc	O	O	O	O
of	of	O	O	O	O
6	6	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
administered	administered	O	O	O	O
safely	safely	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
21-day	21-day	O	O	O	O
schedule	schedule	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
outpatient	outpatient	O	O	O	O
setting	setting	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
recommended	recommended	O	O	O	O
dose	dose	O	O	O	O
for	for	O	O	O	O
phase	phase	O	O	O	O
III	iii	O	O	O	O
studies	studies	O	O	O	O
is	is	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
185	185	O	O	O	O
mg/m2	mg/m2	O	O	O	O
and	and	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
AUC	auc	O	O	O	O
6	6	O	O	O	O
.	.	O	O	O	O

